Author:
Ge Wenzhen,Wu Ning,Jalbert Jessica J,Quek Ruben G W,Liu Jinjie,Rietschel Petra,Pouliot Jean-Francois,Harnett James,Hsu Melinda Laine,Feliciano Josephine L
Reference26 articles.
1. National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer. Version 3.2020; 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 12, 2022.
2. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Updated version published 15 September 2020 by the ESMO guidelines committee; 2018. Available from: https://www.esmo.org/content/download/347819/6934778/1/ESMO-CPG-mNSCLC-15SEPT2020.pdf. Accessed March 12, 2022.
3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
4. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
5. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial